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Fatigue is a frequent and debilitating symptom of multiple sclerosis (MS) with rates ranging
anywhere from 53 to 90%. Despite its high prevalence and grave impact on overall function-
ing and quality of life, the accurate definition, quantification, and etiology of fatigue have
plagued the MS literature and clinical care for decades. With regard to its etiology, MS-
related fatigue has been construed as being either primary or secondary. Primary fatigue is
purported to be related to centrally mediated processes of the disease whereas secondary
fatigue is thought to be a result of the host of factors that may accompany MS (e.g., depres-
sion, sleep disturbance). The present paper focuses on secondary fatigue and the role of
sleep disturbance, in particular. Despite the intuitive assumption that sleep problems could
contribute to fatigue, sleep problems in MS have gone fairly unrecognized until recently.
The present paper provides a brief review of the literature pertaining to the prevalence and
nature of sleep problems in MS as well as their association with fatigue. A replication of
this author’s and others work is presented further demonstrating that sleep disturbance
is a significant contributor to fatigue in MS when taking into account disease variables,
depression, and sleep disturbance.
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INTRODUCTION
Since the first report of fatigue being a prevalent and significant
problem in multiple sclerosis (MS) (1) the definition, accurate
quantification of fatigue in MS, and etiology has perplexed inves-
tigators. To date, nearly every article pertaining to MS-related
fatigue contains some sort of disclaimer regarding our inadequate
definition, lack of appropriate assessment tools, and limited under-
standing of its etiology (2). The present article is no exception.
However, the investigation outlined in this paper is a replication
of previous work demonstrating the fact that when attempting to
at least better understand the etiology of fatigue in MS, consider-
ation should be given to the role that sleep disturbance as it has
been proven to be a significant factor (3).
Despite being the most obvious factor, sleep disturbance or dis-
orders, had initially received fairly little attention as a precipitating
or exacerbating factor of fatigue in MS. Fortunately, following an
editorial by Attarian titled, “Importance of sleep in the quality of
life of multiple sclerosis patients: a long under-recognized issue”
sleep disturbance and its disorders have received significantly more
attention (4). In fact, when conducting a PubMed search with the
terms “MS” and “sleep” in the title, 14 articles have been published
between the years 1987 and 1997 and 15 articles were dated from
1998 to 2008, suggesting approximately 15 published articles on
sleep in MS per decade. However, since Attarian’s editorial in 2009
the number of published articles with MS and sleep in the title is
46. Thus, at this rate, the number of published articles on sleep in
MS over the past 5 years is one a half times more than what was
published in the preceding two decades of the 2009 editorial (see
Figure 1).
These articles have been published worldwide and span the
gamut of looking at the incidence of various sleep disorders to the
role of sleep on quality of life and fatigue to the effects of treating
sleep problems in MS. While the majority of these studies rely on
self-report measurement, some have also included more objective
measures including polysomnography. What is to follow is a brief
review of fatigue in MS, the prevalence and nature of sleep disor-
ders in MS, and the relationship between the two. Study findings
from a recent investigation that replicates previous work demon-
strating that sleep disturbance is a significant contributor to fatigue
in MS when taking into account disease variables, depression, and
sleep disturbance is then presented. Finally, data from a few stud-
ies that have demonstrated that effective treatment of such sleep
problems can result in reduced fatigue among individuals with MS
are provided.
BACKGROUND
FATIGUE IN MS
Fatigue is a frequent and debilitating symptom of MS with rates
ranging anywhere from 53 to 90% (1, 5–9). MS-related fatigue
has typically been construed as being either primary or secondary.
Primary fatigue is purported to be related to centrally mediated
processes of the disease, such as demyelination and axonal loss in
the central nervous system or immunological factors. Secondary
fatigue, on the other hand, is thought to be a result of the host of
factors that may accompany MS (e.g., depression, reduced activ-
ity, medication side effects, sleep disturbance) (10). The present
paper focuses on secondary fatigue and the role of sleep distur-
bance. However, regardless of the exact etiology, fatigue is known
to be extremely detrimental to those with MS with nearly 55% of
patients reporting fatigue to be among their worst symptoms (11)
and 40% describing it as their most disabling symptom (8). MS-
related fatigue has also been shown to have detrimental effects on
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FIGURE 1 | Number of articles published in PubMed with the words
“sleep” and “multiple sclerosis” in the title.
daily functioning, social and occupational obligations, and over-
all well-being. In fact, Freal et al. showed that of the 87% of MS
patients complaining of significant fatigue, 67% reported experi-
encing it on a daily basis and 22% reported that it interfered with
their daily functioning (1). Similarly, Iriarte et al. found that fatigue
produced limitations in daily functioning in 66% of those who
complained of fatigue (12). Of this, 37% reported that it limited
their social activities and 61% reported that fatigue limited their
work. This is consistent with reports showing that fatigue leads to
patients having to cut down on working hours (13) and findings
that individuals with MS report fatigue as the one of the greatest
culprits related to work difficulty or leaving the workforce (14).
Patients also report that their fatigue can result in a lowered sense
of self-worth as well as feelings of shame, sorrow, and anger related
to their perceptions of their fatigue (15). Similarly, fatigue in MS
has been shown to be related to lowered positive affect, psycho-
logical distress, and a sense of loss of control (16). Given its grave
impact, identification of factors associated with fatigue has been
a main priority in research and clinical care among individuals
with MS.
SLEEP DISORDERS IN MS
Current research suggests that anywhere from 19 to 67% of indi-
viduals with MS experience some sort of sleep difficulty (17–32),
with rates as high as 80% in some samples (33). Restless leg
syndrome (RLS) (27, 28, 30), periodic limb movement (PLM)
(21), narcolepsy–cataplexy syndrome, rapid eye movement (REM)
behavior disorder, insomnia, and obstructive sleep apnea (OSA)
(34) have all been reported (see Table 1).
In general, it is believed that individuals with MS are three
times more likely to experience sleep difficulties than controls
(36), though the incidence may be greater for some disorders.
For instance, in a large study consisting of 861 individuals with
MS and 649 healthy controls, it was found that the risk for RLS
was 5.4 times greater for individuals with MS (28).
For many sleep disorders, a direct neurological etiology associ-
ated with MS has been found. For instance, cervical lesions have
been found to be associated with RLS (27) while greater lesion load
in the brainstem and cerebellum has been implicated in PLM (21).
Narcolepsy in MS has been suggested to be related to focal lesions
in the hypothalamus (37). Finally, REM-behavior sleep disorders
in MS have been linked to dorsal pontine lesions (37). While these
sleep disorders have a direct etiology related to specifically to MS,
insomnia, and OSA, which are also common in the general public
have been found to be more prevalent in MS. Insomnia in MS has
been attributed to a multitude of factors, primarily nocturia, leg
spasms, muscle stiffness, pain, depression, and symptomatic MS
medication side effects (32, 38). It has been previously shown that
individuals report bladder incontinence as the greatest contribu-
tor to disturbed sleep, followed by muscle stiffness and leg spasms,
in more than 50% of patients (38). Similar findings were found
by Stanton et al. in which nocturia was the most common cause
of middle insomnia (72%), followed by pain/discomfort (22%).
Nocturia was also the greatest contributor to terminal insomnia
(40%), while anxiety/racing mind accounted for initial insomnia
most often (28%). In general, depression has been shown to be
more related to initial insomnia, while nocturia has been found to
be the cause of middle and terminal insomnia (32). With regard to
OSA, again, reports of OSA in MS are as high as 80% compared to
63% of healthy controls. Causes of OSA in MS may include inac-
tivity due to disability, brainstem lesions that affect the respiratory
centers or nucleus ambiguous, or symptomatic medications that
relax muscle tone in the pharynx (37). While these sleep disorders
are perhaps the most prevalent in MS, they are both amenable to
treatment as will be discussed.
RELATIONSHIP OF FATIGUE AND SLEEP IN MS
Nearly all studies examining sleep problems in MS have been an
attempt to understand its relationship to secondary fatigue and
potential mediating effects, with a few exceptions. In particu-
lar, a number of studies in the MS literature have focused on
sleep disturbance as a significant contributor to fatigue in MS
(23, 24, 30, 32, 39–41). For instance, when comparing fatigued
and non-fatigued individuals with MS, Kaynak et al. found that
those suffering from fatigue experience greater disturbance in sleep
microstructure such as total arousal index (TAI),a measure of sleep
fragmentation, and PLM index (24). Such findings are consistent
with Chen et al.’s findings in which fatigue scores correlated with
PLM index, PLM arousal index, REM latency, and TAI (19). Mori-
era et al.’s study also found that individuals diagnosed with RLS
reported poorer sleep quality, which was in turn related to fatigue
(30). Finally, reports on a self-report measure of OSA have also
been shown to be related to reports of fatigue with more fatigued
individuals being more likely to have elevated scores on this mea-
sure, even when items that could be construed as fatigue were
removed (18, 20).
When constructing a model of fatigue in MS that took into
account disease severity, sleep, and depression, it was found that
sleep disturbance was the greatest predictor of fatigue, accounting
for 24% of the variance followed by depression (10%) and disease
severity (9%) (3). It should be noted that this study utilized mea-
sures in which overlapping items of fatigue, sleep, and depression
were removed from the measures so as to have the purest con-
structs. These findings were later replicated by Ghajarzadeh et al.
in an Iranian sample in which sleep disturbance accounted for
25% of the variance and depression accounted for an additional
9% (42). Such findings suggest that sleep may be the greatest cul-
prit in the experience of fatigue in MS. Within, present findings
demonstrate an additional, third replication of these findings in
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Table 1 | Prevalence of sleep disorders in multiple sclerosis (MS).
Reference Country Size Disorder(s) Prevalence MS Controls
Bamer et al. (17) USA 1062 Disturbed sleepa 52% –
Lunde et al. (26, 35) Norway 90 Poor sleepb 67% 44%
Merlino et al. (29) Italy 120 Poor sleepb 48% –
Chen et al. (19) China 21 Poor sleepb 62% –
Initial insomnia 43%
Middle insomnia 76%
Terminal insomnia 33%
Pokryszko-Dragan et al. (31) Poland 100 Initial insomnia 28% –
Middle insomnia 33%
Terminal insomnia 48%
Stanton et al. (32) USA 60 Initial insomnia 42% –
Braley et al. (33) USA 30 Obstructive sleep apnea 80% 63%
Kaminska et al. (23) Canada 62 Obstructive sleep apnea 58% 47%
Dias et al. (20) USA 103 Obstructive sleep apnea 42% –
Braley et al. (18) USA 195 Obstructive sleep apnea 21% –
Kallweit et al. (22) Germany 69 Sleep disordered breathing 41%
Manconi et al. (27) Italy 861 Restless legs syndrome 19% 4%
Manconi et al. (27) Italy 82 Restless legs syndrome 37% –
Moreira et al. (30) Italy 44 Restless legs syndrome 27% –
Kaminska et al. (23) Canada 62 Restless legs syndrome 27% 6%
Kaynak et al. (7, 24) Turkey 37 Restless legs syndrome 38% 0
Ferini-Strambi et al. (21) Italy 25 Periodic limb movement 36% 8%
Kaminska et al. (23) Canada 62 REM sleep behavior 3% 0
Kaminska et al. (23) Canada 62 Narcolepsy 2% 0
aBased on the medical outcome study sleep (moss) scale.
bBased on the Pittsburgh sleep quality index.
hopes of furthering the increase in attention to sleep problems in
MS and their contribution to fatigue in MS.
RESEARCH DESIGN AND METHODS
PARTICIPANTS
Participants were recruited from local MS clinics and chapters of
the National Multiple Sclerosis Society throughout United States.
Participants were enrolled in a larger study examining factors
associated with employment in MS and thus were all employed,
between the ages of 20 and 64, and diagnosed with definite MS.
PROCEDURES
Participants completed an online survey consisting of several
measures assessing disease variables, psychological functioning,
well-being, health–behaviors, adjustment and coping to MS, and
overall quality of life. All procedures were approved by the Institu-
tional Review Board of the Kessler Foundation. For the purposes of
the present study, participants completed the following measures.
MEASURES
Modified fatigue impact scale
Modified fatigue impact scale (MFIS) is modified form of the
fatigue impact scale (43) that is based on 21 items derived from
interviews with MS patients concerning how fatigue impacts their
lives. It consists of three subscales: physical, cognitive, and psy-
chosocial functioning. Patients are asked to rate on a scale of 0–4
their agreement with the statement and how it impacts them with
“0” being “Never” and “4” being “Almost always.” Recently, it has
been recommended that a cutoff of 38 on the MFIS was most
indicative of significant fatigue in MS (44). Given the potential
overlap of fatigue and depressive symptoms on the psychoso-
cial subscale, the sum of the physical and cognitive subscales was
used for the regression analyses. This score has been termed the
MFISPC.
Pittsburgh sleep quality index
The Pittsburgh sleep quality index (PSQI) is a measure of sleep
disturbance and quality (45). It consists of 19 items that are
summed to create seven“component”scores: subjective sleep qual-
ity, sleep latency, sleep duration, habitual sleep efficiency, sleep
disturbances, daytime dysfunction, and use of sleeping medica-
tion. The sum of scores for these seven components yields one
global score. A cutoff of “5” on the global score is indicative of
being a “poor” sleeper. The global score was used in all analyses.
Chicago multiscale depression inventory
The Chicago multiscale depression inventory (CMDI) was specifi-
cally designed to assess depression in MS and other medical groups
(46). It consists of three subscales: evaluative, mood, and vegeta-
tive. Each subscale contains 14 items and patients are asked to rate
on a scale of 1–5 the extent to which each word/phrase describes
them during the past week, including today with “1” being “Not
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at All” and “5” being “Extremely.” For the purpose of this study,
ratings on the vegetative scale were removed due to confounds
of sleep and fatigue included in the items on this scale. For our
sample, depression was measured by a total score of only the com-
bined evaluative and mood subscales. This score has been termed
the CMDIME.
STATISTICAL ANALYSES
All statistical analyses were conducted using SPSS 21.0 computer
software. Pearson correlations were conducted for all correla-
tional analyses. Independent t -tests were conducted to examine
group differences between the sleep disturbed and non-sleep dis-
turbed groups on demographics, disease variables, fatigue, and
depression. Finally, a stepwise, hierarchical regression was con-
ducted with disease duration, sleep disturbance, and depres-
sion as the independent variables and fatigue as the dependent
variable.
RESULTS
A total of 107 individuals with definite MS were enrolled in the
study. Participants were primarily female (N = 92; 86%) with a
mean age of 44.71 (±9.76) and mean disease duration of 8.91
(±7.13). Per the global score of the PSQI, 61% of participants
were classified as “poor sleepers” and constitute the “sleep dis-
turbed” group. Per the previously recommended cutoff of 38 on
the MFIS, approximately half of the sample (47%) experienced
significant fatigue (see Table 2).
Initial correlations found physical and cognitive fatigue to
be significantly correlated with poor sleep (r = 0.42 and 0.49,
p< 0.001, respectively). A slightly lower correlation was found
with psychosocial fatigue (r = 0.30, p= 0.001). Fatigue was also
found to be associated with all of the subscales of the CMDI (r ’s
ranging from 0.24 to 0.72), with the highest correlations occurring
with the vegetative subscale (r ’s ranging from 0.47 to 0.72), which
is expected given the overlap of fatigue items on the vegetative
scale. Finally, sleep was not found to be related to the mood or
evaluative subscales of the CMDI but was significant correlated
with the vegetative subscale (r = 0.65, p< 0.001). Again, this is
greatly influenced by item overlap. When looking at the measure
scores used in the regression analyses (MFISPC and CMDIME)
the correlations between fatigue, depression, and sleep remained
(see Table 3).
Stepwise regression analyses found that sleep disturbance
accounted for 25% of the variance in predicting fatigue, followed
by depression, which accounted for an additional 7%. Together,
they accounted for 32% of the variance, while disease duration
did not contribute to predicting fatigue (see Table 4).
Such findings are a near replication of previous findings, sug-
gesting that sleep disturbance is the greatest predictor of fatigue
in MS when examined among disease variables and depression,
and accounts for a quarter of the variance. However, it should be
noted that there are limitations of the present data, including the
lack of objective measures of disease severity, fatigue, and sleep dis-
turbance and the use of self-report surveys. There is also the lack
of information pertaining to participants’ medication load. Such
factors may also contribute to sleep problems in MS. Though,
even with the limitations of the present data, clinical findings, and
Table 2 | Participant demographics and group comparisons on disease
variables, sleep, fatigue, depression.
Total sample
(N =107)
mean (SD)
Range
Age 44.71 (9.76) 23–64
Disease duration 8.91 (7.13) 0–31
PSQI total 7.07 (4.07) 1–18
MFIS physical 17.47 (8.00) 0–35
MFIS cognitive 16.00 (9.34) 0–38
MFIS psychosocial 3.40 (1.92) 0–8
CMDI mood 22.83 (10.07) 14–68
CMDI evaluative 19.38 (8.19) 14–61
CMDI vegetative 33.70 (9.72) 17–53
Not sleep
disturbed
(N =42)
mean (SD)
Sleep
disturbed
(N =65)
mean (SD)
t -test, sig.
Age 46.00 (10.32) 43.88 (9.36) t =1.10, p=0.274
Disease duration 8.19 (6.07) 9.38 (7.75) t =−0.84, p=0.401
PSQI sleep
duration
0.24 (0.43) 0.95 (0.99) t =−5.12, p<0.001
PSQI sleep
disturbances
1.12 (0.45) 1.60 (0.49) t =−5.18, p<0.001
PSQI sleep latency 0.50 (0.59) 1.49 (0.89) t =−6.93, p<0.001
PSQI daytime
dysfunction
0.74 (0.63) 1.48 (0.77) t =−5.42, p<0.001
PSQI sleep
efficiency
0.10 (0.48) 1.11 (1.25) t =−5.88, p<0.001
PSQI sleep quality 0.60 (0.50) 1.65 (0.80) t =−8.39, p<0.001
PSQI sleep
medication
0.24 (0.66) 1.20 (1.29) t =−5.08, p<0.001
PSQI global score 3.36 (1.27) 9.48 (3.38) t =−1.50, p<0.001
MFIS physical 14.81 (7.82) 19.18 (7.70) t =−2.84, p=0.006
MFIS cognitive 12.62 (7.47) 18.18 (9.82) t =−3.31, p=0.001
MFIS psychosocial 2.79 (1.88) 3.80 (1.85) t =−2.75, p=0.007
CMDI mood 21.02 (9.85) 24.00 (10.11) t =−1.50, p=0.136
CMDI evaluative 18.26 (8.14) 20.10 (8.20) t =−1.14, p=0.257
CMDI vegetative 28.07 (5.22) 37.34 (10.24) t =−6.16, p<0.001
PSQI, Pittsburgh sleep quality index; MFIS, modified fatigue impact scale; CMDI,
Chicago multiscale depression inventory.
research supporting, the significant role of sleep on MS-related
fatigue should hopefully compel practitioners to consider more
routine assessment of sleep and referral to sleep studies, when
warranted, or when presented with a patient complaining of sig-
nificant, debilitating fatigue that may exceed what one expects in
MS. Consideration should also be given when there is any indica-
tion from the patient or bed partner that they patient may have
a concomitant sleep disorder. Lunde et al. provide a very thor-
ough review of how best to begin to assess sleep problems in
MS as there are presently no specific guidelines. Practitioners are
urged to refer to the full guidelines provided by Lunde et al. when
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Table 3 | Correlations of fatigue, depression, and sleep disturbance.
Mood Evaluative Vegetative Sleep MFISPC
Physical 0.32** 0.29** 0.50** 0.42** –
Cognitive 0.33** 0.24* 0.72** 0.49** –
Psychosocial 0.37** 0.29** 0.47** 0.30** –
Mood – – – 0.14 –
Evaluative – – – 0.13 –
Vegetative – – – 0.65** –
MFISPC – – – 0.51** –
CMDIME – – – 0.14 0.34**
Physical, MFIS physical subscale; Cognitive, MFIS cognitive subscale; Psy-
chosocial, MFIS psychosocial subscale; Mood, CMDI mood subscale; Evalua-
tive, CMDI evaluative subscale; Vegetative, CMDI vegetative subscale; Sleep,
PSQI global score; MFISPC, MFIS Physical+Cognitive score; CMDIME, CMDI
Mood+Evaluative score.
*Significant at the 0.05 level.
**Significant at the 0.01 level.
Table 4 | Stepwise hierarchical regression predicting fatigue with
disease duration, sleep, and depression as the independent variables.
B SE (B) β R2
Step 1
PSQI 1.95 0.32 0.51** 0.25
Step 2
PSQI 1.80 0.31 0.47**
CMDIME 0.24 0.07 0.28** 0.32
PSQI, Pittsburgh sleep quality index global score; CMDIME, Chicago multiscale
depression inventory mood and evaluative subscales.
**Significant at the 0.01 level.
treating individuals who complain of significant fatigue, daytime
sleepiness/dysfunction, and sleep difficulties. We turn now to a
brief discussion pertaining to the findings that proper assessment
and treatment of sleep problems in MS may result in reduced
fatigue.
TREATING SLEEP PROBLEM IN MS
Additional support for addressing sleep problems as an underlying
cause of fatigue is more recent findings that effective treatment
of sleep problems actually results in reductions in self-reported
fatigue and sleepiness in MS. More specifically, in a controlled,
non-randomized clinical study, Cote et al. evaluated 62 individuals
with MS and referred those suspected of having a sleep disor-
der for evaluation and treatment at a sleep disorder clinic. Of
the 39 (63%) who were diagnosed with a sleep disorder, 21 were
treated and 18 were not. Treatment consisted of sleep hygiene
advice and then further treatment, which was dependent on the
nature of the sleep disorder and included continuous positive air-
way pressure (CPAP) or other position devices for sleep apnea;
treatment of exacerbating factors (e.g., iron or B12 deficiency)
and/or pramipexole for RLS; clonazepam for REM behavior dis-
ordered sleep; and cognitive behavioral therapy for insomnia.
Three months follow-up revealed a significant improvement in
fatigue as well as sleepiness, subjective sleep quality, depression,
pain, and quality of life among those who were treated. Those not
treated did not demonstrate such improvement (39). In another
study, progressive muscle relaxation was also shown to improve
sleep quality and reports of fatigue in a sample of 32 individ-
uals with MS (47). More specifically, the average score of the
fatigue severity scale (48) decreased from 5.75± 0.95 (a score
above the recommended cutoff of 4) to 3.81± 1.30 (p< 0.001).
Finally, Veauthier et al. evaluated the effectiveness of compliance
with treatment imposed by a sleep specialist in 42 individuals
with MS. Those who were described as having “good compliance”
to the treatment demonstrated a significant, 15-point difference
on the MFIS. Such significant findings were not found in those
with no to moderate compliance or those without a sleep disor-
der that were followed over the same time period (40). While it
is possible, there may be some expectation bias among those that
adhere to their treatment and subsequent ratings of improvement,
it should be noted that those who were partially compliant to their
treatment also demonstrated an improvement in fatigue, albeit
not statistically significant. Together, these findings further stress
the importance of proper assessment and effective treatment of
sleep problems among individuals with MS complaining of sig-
nificant fatigue and suggest that effective assessment, referral, and
treatment of sleep problems in MS are likely to yield significant
results.
In sum, the present paper aimed to again increase our aware-
ness of the prevalence and etiology of sleep problems in MS and
more importantly, its contribution to the experience of fatigue,
one of the most disabling symptoms associated with MS. The
study described within also provides further support of the role of
sleep on fatigue and the importance of its assessment. In science,
observation is the first step in questioning and aiming to under-
stand a phenomenon. MS-related fatigue has been a construct that
has perplexed investigators for decades. Over the past few years, the
field has begun to test the hypothesis that sleep may be a significant
contributor of fatigue in MS. These observations and subsequent
findings have yielded positive results. However, the next,and some-
times neglected aspect of science, is replication. Here, findings
show a third replication of study findings that consistently demon-
strate that sleep problems account for approximately a quarter of
the variance of fatigue in MS.
Based on these findings, further research is warranted in which
we continue to examine and model the contributing factors of
fatigue and sleep in MS in hopes of indentifying the factors
and ultimately, treating them. In doing so, future studies should
address some of the methodological limitations of past studies,
including reliance on self-report measures of sleep and fatigue.
Objective measurement of sleep and fatigue, while time consum-
ing and costly, are likely to yield more substantial findings. A few
preliminary studies demonstrating the effects of treating sleep on
fatigue were also provided within. Further intervention studies are
warranted with larger sample sizes and great characterization of
the sleep problems as well as the active ingredients of treatment.
With such advances, it is hoped that we will see an increase in
the assessment, referral, evaluation, and treatment of sleep prob-
lems in MS and ultimately be capable of improving the lives and
well-being of individuals with MS.
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